- Investing Ideas
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
2
0 new
High return on equity, past performance and sound balance sheet.
2 companies
Exelixis
Market Cap: US$10.7b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$41.24
7D
-0.7%
1Y
12.5%
Rigel Pharmaceuticals
Market Cap: US$479.4m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$25.95
7D
-10.1%
1Y
28.9%